What a peptide blend is
A peptide blend is a single vial containing two or more distinct peptides, supplied together as one lyophilised solid in a fixed nominal ratio. The total fill on the label – for example 70 mg or 80 mg – is the sum of the components, not the amount of any one of them.
Blends are supplied for laboratory work that calls for a defined mixture as a reagent or reference material. The published research on these compounds generally concerns the individual peptides rather than the combinations, so the literature for each component is the relevant starting point; every Britpep blend page links to its component products.
What the trade names refer to
Several blends are widely known by short trade nicknames rather than by their components. These names are not scientific or regulatory designations, and they do not define a ratio on their own – the composition stated by the supplier and on the certificate is what identifies the material. At Britpep:
- KLOW 80 (sometimes just “KLOW”) refers to our BPC-157 / GHK-Cu / TB-500 / KPV blend, 80 mg per vial.
- GLOW 70 (or “GLOW”) refers to our BPC-157 / GHK-Cu / TB-500 blend, 70 mg per vial.
- The Wolverine blend is a name used for BPC-157 / TB-500.
- CJC/Ipa is shorthand for CJC-1295 (without DAC) / Ipamorelin, also written Mod GRF 1-29 / Ipamorelin.
- Semax / Selank combines the two heptapeptide analogues.
Because the same nickname may be used by different suppliers for mixtures with different ratios, it is worth confirming the stated composition rather than relying on the name. For background on the individual components, see our articles on BPC-157, GHK-Cu and thymosin β4 and TB-500.
Why blends are harder to characterise
For a single peptide, an HPLC purity figure is the main peak as a share of all integrated peaks. In a blend there are several intended main peaks, and each component brings its own family of synthesis-related impurities – deletion and insertion sequences, diastereomers and degradation products [1]. Separating every intended component from every impurity in one chromatogram is a more demanding analytical problem, and a peak that co-elutes with another can be miscounted.
Mass spectrometry helps by assigning a mass to each peak, so that each intended component can be identified and unexpected species flagged [1]. Pharmacopoeial thinking about peptide specifications treats identification, purity and content as separate questions [2], and the same distinction applies to each component of a mixture: confirming that every peptide is present is not the same as measuring how much of each is present.
Stability considerations in a mixture
Components in a blend share one solid matrix and, once dissolved, one solution. The chemical degradation pathways described for peptides and proteins – deamidation, oxidation, hydrolysis and aggregation – depend on the sequence of each molecule and on conditions such as temperature, pH and moisture [3]. A mixture is therefore only as robust as its least stable component under the chosen conditions.
Residual moisture and storage temperature remain the main controllable factors for a lyophilised solid [4]. Store blend vials as stated on the label and certificate, and see our guide to storing lyophilised peptides for the general principles.
What to look for on a blend certificate
- The lot number, matching the vial label.
- The stated components and nominal amount of each, adding up to the vial fill.
- Identity evidence for each component, typically observed masses from mass spectrometry.
- An HPLC chromatogram showing how the components and impurities are separated, with the method and wavelength.
- The storage condition.
Britpep blend lots are listed in the COA checker by the batch number printed on the label, and our guide to reading a COA explains each field in more detail. Blends, like all our products, are supplied for laboratory research use only.
References
- D'Hondt M, Bracke N, Taevernier L et al.. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014; 101:2-30. doi:10.1016/j.jpba.2014.06.012. PubMed 25044089
- Vergote V, Burvenich C, Van de Wiele C et al.. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009; 15:697-710. doi:10.1002/psc.1167. PubMed 19750489
- Manning MC, Chou DK, Murphy BM et al.. Stability of protein pharmaceuticals: an update. Pharm Res. 2010; 27:544-75. doi:10.1007/s11095-009-0045-6. PubMed 20143256
- Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000; 203:1-60. doi:10.1016/s0378-5173(00)00423-3. PubMed 10967427
References were checked against PubMed and official UK sources at the time of writing. Summaries describe what each source reports; they are not claims about Britpep products.
